Daytrana Side Effects
Serious Adverse Side Effects
Daytrana | Methylphenidate transdermal patch has some very serious adverse side effects associated with it, such as:
- Dermatological side effects such as skin inflammation after application of patch
- Endocrine metabolic side effects such as decreased body growth
- Neurological side effects such as convulsions and tics
- Psychiatric side effects such as having manias and psychotic behavior
- Other side effects such as overdose and drug abuse
Common Adverse Side Effects
More common and less severe adverse side effects associated with
Daytrana | Methylphenidate transdermal patch include:
- Dermatological side effects such as redness at application site
- Endocrine metabolic side effects such as decrease in weight
- Gastrointestinal side effects such as decrease in appetite, nausea and vomiting
- Neurological side effects such headache and insomnia
- Psychiatric side effects such as involuntary crying
- Respiratory side effects such as nasal congestion and cold
Warnings & Recalls for Daytrana
Black Box Warning
Daytrana | Methylphenidate transdermal patch has a “black box” warning associated with it that says that it must be administered with the utmost caution to patients with a known or suspected history of alcoholism or drug abuse. Chronic abuse of this drug can lead to a tolerance to this drug, rendering it ineffective for its proper use. Furthermore, there can also be a psychological dependence on
Daytrana | Methylphenidate transdermal patch with exhibitions of abnormal behavior. True psychotic episodes can occur. Careful supervision is required in the withdrawal from this drug and should be done gradually as severe depression can occur.
Contraindications
Daytrana | Methylphenidate transdermal patch has reported contraindications to it that hinder a patient’s ability to take this drug. They include:
- Patients with agitation, anxiety or tension
- Patients with glaucoma
- Patients with a hypersensitivity to Methylphenidate or other component ingredients in this drug
- Patients who use MAO inhibitors
- Patients with motor tics
- Patients with a family history or diagnosis of Tourette’s syndrome
Who Should Not Take This Drug
The following patients with these certain preexisting conditions should never take this drug:
- Patients with a cardiovascular disease
- Patients with drug abuse issues or alcoholism
- Patients with cardiac abnormalities
- Patients with contact sensitization
- Patients who have convulsions
- Patients who are exposed to the heat for long durations are advised not to take this drug
- Growth suppression can occur with long-term use
- Patients with hypertension
- Patients with psychosis
- Patients who are prone to seizures
Daytrana Treatment and Use
Daytrana | Methylphenidate transdermal patch is a drug that is prescribed for pediatric to adolescent patients (specifically ages 6 to 17) who have difficulty with concentration and who are diagnosed as having ADHD, or attention deficit hyperactivity disorder. This drug was first approved in April of 2006 by the FDA and was developed, manufactured and marketed by Noven Pharmaceuticals. The necessity of having this drug come in a transdermal patch form is for the reason that some patients have difficulty with compliance or cannot tolerate oral forms of drugs meant to treat ADHD.
Daytrana | Methylphenidate transdermal patch was originally meant to be applied for a duration of 12 hours, however with a bit of pressure from the FDA, a formulation of Daytrana | Methylphenidate transdermal patch for the duration of 9 hours came into the market.
Please refer to the “warnings and recalls” tab to get more information on Daytrana | Methylphenidate transdermal patch and its “black box” warning.
How This Drug Works
The mechanism of action for Daytrana | Methylphenidate transdermal patch is that since it is a central nervous system stimulant, it acts on the brain stem arousal system and also the cortex. What exactly is the mode of therapeutic action has still yet to be understood, but it is thought that Daytrana | Methylphenidate transdermal patch blocks reuptake of dopamine and norepinephrine into the presynaptic neuron, thereby increasing concentrations of certain substances that make this drug effective in treating the ADHD symptoms of pediatric and adolescent patients.
Dosage Information
The safety and effectiveness of Daytrana | Methylphenidate transdermal patch in pediatric patients under the age of 6 has not been established, hence patients in this age criterion typically don’t receive this drug.
In children aged 6 to 17 who’ve got ADHD, the following treatment dosage through transdermal patches have been established. Daytrana | Methylphenidate transdermal patch is meant to be applied topically 2 hours before needed effect and is removed 9 hours after the daily application. The following dosage forms are approved by the FDA as well as the manufacturer:
- Week 1: 10mg patches
- Week 2: 15mg patches
- Week 3: 20mg patches
- Week 4: 30mg patches
